OCEAN study for EGPA

Trial Objective

OCEAN study for EGPAPeople with eosinophilic granulomatosis with polyangiitis (EGPA) are needed for the OCEAN clinical trial. The study compares two medications:  mepolizumab (NUCALA), which is administered by an injection once a month, and depemokimab, an investigational medication that is injected twice a year. Researchers want to understand if depemokimab is as safe and effective as mepolizumab. Volunteers will receive a blood draw and will be randomly assigned to receive an injection of one of the two medications.

Enrollment

This trial is active and currently recruiting.

Who Can Participate

Adults with EGPA that has worsened or returned after previous treatment and are taking a corticosteroid or immunosuppressant

Age: 18+    Gender: Any Gender


Estimated Time Commitment

Once a month visits for approximately 15 months



Compensation

Provided

Trial Contact

For more information, contact:

Allen Stevens
303.398.1268

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

GSK

Principal Investigators

Co-Investigators


Request More Information


*
*
*
*
 I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: